Theraxium Oncology provides actionable answers,
whenever patients and care teams need them,
to enhance care and collaboration.
Digital therapeutics in oncology help empower patients to self-manage their symptoms. Theraxium Oncology is a platform that allows to create those digital therapeutics. They combine a prescription app for patients, a web portal for health care teams.
Theraxium Oncology also embeds specific modules to design and simulate new algorithms, predefined UX templates and configurable / interoperable workflows.
Voluntis has leveraged these modules to design an off-the-shelf library of clinical algorithms, which can be further customized.
A digital therapeutic is based on a mobile app for patients and a web portal for HCPs. It awaits in patients’ pockets, ready to provide answers whenever they need them. Whether they’re starting a new treatment or already in therapy, experiencing symptoms such as fever or high blood pressure, patients receive personalized insights to manage their issues. Recommendations are made in accordance with the treatment plan set up by their care team. Leveraging embedded clinical algorithms, the application can help patients:
Digital therapeutic aims to improve quality of life, treatment adherence and collaboration with care teams while lowering costs.
Know what you need to, when you need to, so you can make the most informed decision. Digital therapeutic creates reports and analyzes how patients are living with their symptoms in real time, so that care teams have the power to:
Care teams can better anticipate and implement responsive care strategies that work to serve each patient’s individual needs when they need it most. They can also optimize their time by spending more of it with patients who need assistance and talking with patients during their appointments rather than collecting data.
We’ve called on some of the leading minds in cancer care to help us design the clinical principles underlying our digital therapeutics. They’re the members of our clinical advisory board, which gathers experts from preeminent institutions in cancer treatment all over the United States and Europe.
Dr. Matti Aapro is presently Dean of the Multidisciplinary Oncology Institut at Genolier. He is also a Board Member of ECCO (European CanCer Organisation) and he serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member. He is past-President of the Multinational Association for Supportive Care in Cancer (MASCC). He is a member of the ESMO Faculty and chairs the ESMO 2017 Supportive/Palliative Care track. Dr. Aapro is Editor of Critical Reviews in Oncology/Hematology and the Journal of Geriatric Oncology. He has authored more than 350 publications and his major interests are new drug development, breast cancer, cancer in the elderly, and supportive care.Close
Dr. Wei Ai graduated from Stanford University School of Medicine in 2000. Dr. Ai is affiliated with UCSF Medical Center Mount Zion and UCSF Medical Center Parnassus. She has developed and led a collaborative multi-disciplinary research program in cutaneous T cell lymphomas that includes a laboratory-driven translational component, investigator-initiated clinical trials, and an epidemiology and outcomes research dimension with a successful track record in each of these arenas. She has published 39 peer-reviewed articles and presented her original research at numerous conferences. Dr. Ai has established an international reputation as a leader in clinical research and clinical care of patients with lymphoma. She has received awards from ASCO and AACR.Close
Dr. Paolo Bossi is a medical oncologist devoted to head and neck cancer treatment. He is particularly dedicated to rare head and neck cancers (paranasal sinus cancer, adnexal cancer, nasopharyngeal cancer, salivary gland cancer). He is currently evaluating the impact of treatment and treatment-induced toxicities in elderly patients. He is greatly committed to supportive care, and is studying the impact of the microbioma in the development of treatment-related toxicities. He is also dedicated to non-melanoma skin cancer, with a strong commitment to translational evaluation of the response to new drugs.Close
April is employed by the University of Texas MD Anderson Cancer Center, as Coordinator for Quality Management within the Physicians Network. She reviews and audits medical records for quality measures including: QOPI participation, data entry and review of oncology practices according to national standards. Prior positions include Senior Research Nurse in the Gastrointestinal Medical Oncology Division at UT MD Anderson and primary clinical outpatient nurse for Dr. James Yao’s neuroendocrine practice and Dr. E. Scott Kopetz’s metastatic colorectal practice. April has been involved in a number of publications and poster presentations as well as speaking and training activities.Close
Dr. Arvind arari, a medical oncologist, treats cancers of the colon, rectum, pancreas, liver and neuroendocrine tumors at MD Anderson Cancer Center. He completed a Fellowship in Human Genetics at the University of Pittsburgh and a Fellowship in Oncology at the University of Colorado. He is a member of SWOG as well as Co-Chair of the MD Anderson Neuroendocrine Multidisciplinary Conference. He has received multiple honors and awards from associations such as AACR and ASCO. He has authored over 50 publications including articles, abstracts, and book chapters related to cancers of the GI tract. He acts as a reviewer for the Annals of Oncology, the Annals of Surgical Oncology and Neuroendocrinology. Dr. Dasari speaks internationally at conferences and seminars related to GI Cancers and is a member of associations such as the AMA, ASCO, AACR, NANETS and others.Close
Professor Dame Lesley Fallowfield has published over 360 papers and books. She lectures and runs training workshops throughout the world in psychosocial oncology, quality of life assessment and communication skills. In 2010, she was awarded the Pfizer/BOA Excellence in Oncology Lifetime Achievement Award. Dame Lesley’s research interests include assessment of Patient Reported Outcomes (PROs), supportive interventions for symptoms & side-effects of cancer and its treatment. She creates innovative training courses and materials to assist healthcare professionals’ communication with patients, their families and clinical colleagues.Close
Prof. Gascón holds the position of Director, Division of Medical Oncology and, Scientific Coordinator of the Hematology-Oncology Department, at the Hospital Clinic in Barcelona. He is board-certified in internal medicine and hematology, as well as medical oncology. From 1985 to 1999, he was the Director of the Division of Hematology-Oncology at UMDNJ-New Jersey Medical School where he graduated with a PhD. He has published more than 200 papers in peer-reviewed journals. His main clinical interests are in breast and colorectal cancer and in palliative care, in particular bone marrow toxicities.Close
Dr. Geller completed a Galloway Fellowship in the Department of Surgery, Gynecology Division at Memorial Sloan Kettering in 2000. Dr. Geller holds a Master of Science in Clinical Research and specializes in the treatment and management of gynecologic malignancies. Dr. Geller has received independent funding for her projects, has published in peer-reviewed journals and presented her research at scientific meetings. She is the primary investigator on multiple clinical trials involving the use of natural killer (NK) cell immunotherapy for women with recurrent ovarian cancer. Her translational research is funded by the American Cancer Society (ACS) and involves the investigation of immunotherapies in an ovarian cancer mouse model. She currently holds a Department of Defense grant funding the creation of an interactive mobile phone application to educate women with ovarian cancer on the importance of genetic counseling for hereditary cancers.Close
Professor Karin Jordan is the leading senior physician of the Department of Hematology and Oncology at the University Hospital in Heidelberg, Germany. Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel in 2009 and 2015 as well as a member of the ASCO antiemetic guideline panel. She is the ESMO Faculty coordinator for Supportive & Palliative Care and the ESMO Clinical Practice Guidelines subject editor for the supportive care section. Professor Jordan has authored and co-authored more than 120 publications. Her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.Close
Dr. Joseph Kim, a medical oncologist, specializes in the treatment of genitourinary cancers. While at the NCI, Dr. Joseph Kim was involved in clinical development of novel immunotherapies, such as therapeutic cancer vaccines and immune checkpoint inhibitors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). He is an active member of Society of Immunotherapy of Cancer and ASCO. He is currently on the protocol review board at Yale University. Dr. Kim has been involved in numerous clinical trials as both the Principal investigator and sub-investigator. He has been invited to speak at both international and national cancer conferences and has authored or co-authored approximately 20 articles, chapters or case studies.Close
Krystal has worked at Barnes Jewish Hospital in St. Louis, MO, since 2004. She is passionate about caring for patients with gynecological cancers. Krystal is on the board of the St. Louis Ovarian Cancer Awareness Organization. She has experience in clinical trial coordination and administration of chemotherapy.Close
Sarah has worked at Fox Chase Cancer Center since 2005. She was promoted to Director of Case Management in 2009. Her experience in case management includes assisting patients and their families in all aspects of discharge planning, collaborating and troubleshooting to ensure smooth transitions of care, and ensuring payer authorization through clinical reviews and other third party requirements. She has a strong knowledge of Inter-qual for clinical decision support. She participates in orienting new medical and surgical residents, fellows and nurses to the role and responsibilities of the Case Management staff. She is also responsible for conducting root cause analysis of hospital readmissions, creating and following through on length of stay reduction projects.Close
Deborah was the Nurse Practitioner for Dr. Willis at Cancer Treatment Centers of America. In this position, she evaluated and treated complex oncology patients. Deborah has also worked with the University of Pennsylvania assisting with development and implementation of affiliated hospital system competencies for oncology. She has worked extensively with the Veterans Administration Medical Center in Philadelphia and Boston in building a multidisciplinary hospice program and coordinating care for veterans receiving oncology treatment. Deborah has her Advanced Practice Oncology Certification as well as her Family Nurse Practitioner certification. She has published and spoken extensively on oncology practices throughout the US.Close
Dr. Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medicinal approach to a selection of novel therapies as well as understanding biologic mechanisms of drug sensitivity and resistance. Dr. Yu is involved with a number of national organizations such as ASCO and NCI. He holds positions as a Special Clinical Expert on the Steering Committee for GU Cancers at the NCI and is an Advisory Member on the Board of the Society of Urology Oncology. Dr. Yu has published over 200 articles, abstracts and posters and has been invited to speak at conferences and workshops internationally.Close
Over the past four years, we’ve continuously incorporated feedback from leading cancer care centers, patients and care teams to create a system that not only works with existing clinical workflows but also meets user satisfaction.
Our Theraxium platform is the backbone for all our oncology solutions, providing a robust infrastructure and rapid deployment for each digital therapeutic we create. The 50 solutions it has deployed have managed over 600,000 patients in 10 countries.
Voluntis is more than a technology innovator. With in-house clinical affairs, regulatory, market access and real-world evidence specialists, our teams carry digital therapeutics from clinical design to market launch to patient support.
Theraxium has been used as the backbone for a pipeline of oncology digital therapeutics
AstraZeneca selected Theraxium Oncology to design a digital therapeutic that supports women undergoing treatment for ovarian cancer.
Voluntis and Bristol-Myers Squibb Company announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients.
Voluntis will collaborate with Novartis to evaluate the use of Voluntis’ digital therapeutic platform for Breast Cancer patients with the goal to empower patients with tools to more effectively manage symptoms and, thereby, improve patient experience and outcomes.
First FDA Class II Software-as-a-Medical Device to be Marketed for Use Across All Cancer Indications.
The award recognizes outstanding partnerships between French and North American entities to improve health care. It was presented at a ceremony in New York City on October 25, 2018.
Voluntis launches its Theraxium Oncology offer, a breakthrough technology that leverages digital therapeutics to empower patients to self-manage the symptoms they experience when receiving cancer treatments, in coordination with their care teams.
Symptoms reported via eCO allowed rapid provider response and a positive overall patient experience. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their healthcare team.
A multi-center clinical study has been initiated to evaluate adherence to the ZEMY solution as well as potential improvement in patients’ quality of life. Voluntis and Roche will seek regulatory clearance for this innovative software medical device.
Results of the pilot study to evaluate the feasibility, usability, and perceived satisfaction with eCO (eCediranib-Olaparib), a mobile application for side effect monitoring and reporting, in women with recurrent ovarian cancer
Do you share our desire to improve symptom management in oncology? Tell us about it!